Abstract
Introduction

Liver fibrosis is the main cause of organ failure in chronic liver disease. It can result from reiterated tissue damage due to infection (mostly hepatitis B virus [HBV] and hepatitis C virus [HCV]), toxic/drug exposure or metabolic or autoimmune disorders [1]. After two or three decades, patients become cirrhotic and are at high risk of developing hepatocellular carcinoma (HCC). Liver fibrosis is due to the progressive accumulation of extracellular matrix (ECM) proteins in the liver sinusoids. During progression of hepatic fibrosis, sustained inflammation activates hepatic stellate cells (HSC), leading to their conversion into a fibrogenic and proliferative cell type. Activated HSC produce large amounts of collagen and thereby serve as the principal mediators of fibrogenesis [2]. Chronic hepatitis that leads to fibrosis is characterized by a persistent inflammatory infiltrate and a Th2 polarized immune response. In contrast, Th1 cytokines generate a rapid and intense inflammatory response but cause little fibrosis. Thus, Th2 cytokines such as interleukin (IL)-6, IL-4 and IL-13 promote HSC proliferation, transforming growth factor (TGF)-␤ synthesis and fibrogenesis
. [4] and DVS 27 [5] . IL-33 is preferentially localized in the high endothelial venules of human tonsils, Peyer's patches and lymph nodes [4] . [6] . It is a dual-function protein that may act both as an intracellular nuclear factor and a cytokine. Indeed, IL-33 is an abundant chromatin-associated factor in the nucleus of endothelial cells exhibiting transcriptional repressor properties [7] . [8] . In the presence of IL-33, ST2 binds IL-1RAcP and allows signalling through mitogenactivated protein kinases and NF-B [8, 9] . Soluble IL-33 increases the secretion of Th2 cytokines both in vitro and in vivo [8] . A recent study showed that IL-33 also reduces the development of atherosclerosis, a chronic inflammatory disease, through induction of IL-5 [10] . Heart failure and cardiac fibrosis are associated with the production of IL-33 from the cardiac fibroblasts [11] . The involvement of ST2 receptor was also investigated in human fibrotic diseases. Tajima et al. [12] 
IL-33, a pro-Th2 cytokine, is among the most recent cytokines to be identified. IL-33 belongs to the IL-1 family. It is also known as nuclear factor of high endothelial venules (NF-HEV)
Recently, IL-33 has been observed by immunochemistry as constitutively expressed in the nucleus of endothelial cells from both small and large blood vessels of various tissues including human normal liver (NL)
Interestingly, IL-33 has also been identified as the natural ligand for
Human liver biopsies
Liver tissue samples were obtained from 34 patients with HCC undergoing surgical resection of the tumour as previously described [14] . [17, 18] . We measured levels of ALT (Fig. 1B) . In contrast, no significant change in IL-1RAcP expression was detected (Fig. 1B) . We also noticed that the basal expression of collagen 1A2 mRNA is significantly increased after 12 weeks (0 hr) and 13 weeks (7 days) in CCl4-treated mice (Fig. 1C) (Fig. 2A) . We studied IL-33 protein levels by immunohistochemistry in fibrotic livers (Fig. 2B) . IL-33 protein was detected in vascular endothelial cells (Fig. 2Bb, g ), in sinusoidal cells (Fig. 2Ba, b) , in cells distributed along fibrous septa bridging portal tracts (Fig. 2Bc, f, h ) and in immune infiltrates (Fig. 2Bb) (Fig. 2Bd, e) (Fig. 3Aa, c) (Fig. 4A) . (Fig. 5A) , as previously described [4] . In fibrotic liver (Fig. 5B, C) , IL-33 staining was concentrated in endothelial cells from portal vessels (Fig. 5Ca ) and in sinusoids (Fig. 5Cb) (Fig. 5Cc, d ). As expected, ␣-SMA staining was much more intense in fibrotic liver than in NL (Fig. 6A ) and was associated with fibrous scars, where activated HSC produce collagen in excess. Serial sections immunolabelled with anti-IL-33 (Fig. 6Ba, c) and anti-␣-SMA (Fig. 6Bb, d) (Fig. 6C) . (Fig. 7A) 
Results
IL-33 is overexpressed in mouse liver fibrosis
Carbon tetrachloride-induced liver fibrosis model is a well-established model for studying liver inflammation and fibrosis
Non-tumoral fibrotic livers were separated as a function of the severity of fibrosis, and identified as fibrosis (F0-F3) or cirrhosis (F4). IL-33 and ST2 are clearly associated with both fibrosis and cirrhosis (Fig. 4B). In contrast, IL-1RAcP mRNA levels did not significantly differ between the fibrotic liver groups. In conclusion, production of IL-33 and its receptor ST2 are linked to the fibrosis process.
IL-33 and ST2 expression in human liver
To identify the cellular source of human IL-33, we determined its localization by immunohistochemistry in normal and fibrotic livers. Before, human tonsils sections were used as positive controls and IL-33 was found in the high endothelial cell venules of the T territory and had a nuclear localization
Fig. 1 IL-33 mRNA is overexpressed in mouse liver fibrosis. (A) Blood levels of ALT and AST in C57Bl/6 mice treated for 12 weeks with CCl4. Real-time PCR analysis of mRNA levels of IL-33, ST2 and IL-1RAcP (B) and collagen 1A2 (C) in oil control (Oil) and livers from
001). Graphic representation of the Spearman's rank correlation coefficient between IL-33 and ST2 (B) and between IL-33 and collagen 1A2 (C).
Fig. 2 IL-33 distribution in mouse liver sections. (A) Photomicrographs of liver sections stained with Sirius red from mice treated for 12 weeks with CCl4 (right) or oil (left). (B) Immunohistochemistry on frozen liver sections from oil-or CCl4-treated mice, killed 24 hrs after the last administration of CCl4 as indicated, was performed with the non-specific IgG control, the antimouse IL-
Fig. 4 IL-33 and ST2 are overexpressed in human fibrotic and cirrhotic liver. (A) Real-time qPCR analysis of IL-33, ST2 and IL-1RAcP mRNA levels in NL (n ϭ 6), NT (n ϭ 28) and HCC (n ϭ 22). (B) Real-time qPCR analysis of IL-33, ST2 and IL-1RAcP mRNA levels in NL (n ϭ 6) and in NT classified as fibrosis (F0-F3; n ϭ 8) or cirrhosis (F4; n ϭ 20). Results are expressed as ratios relative to 18S. P-values for differences between populations were determined with the Student-Newman-Keuls multiple comparison test (*P
Ͻ
Furthermore to identify the cellular target of human IL-33 in human fibrotic liver, we determined the localization of the specific IL-33 receptor, ST2 by immunohistochemistry in fibrotic liver sections. ST2 staining was associated with immune infiltrate
, as well as was the pan-T lymphocyte marker, CD3 (Fig. 7B). Co-staining experiments revealed that ST2
ϩ cells are T lymphocytes (Fig. 7C) . (Fig. 8Cc-f) . 25% of the NPC were IL-33 ϩ and 87% of the IL-33 ϩ cells were also positive for CD31 (Fig. 8Cg) . We did not detect IL-33 in leucocytes, macrophages or Kupffer cells (Fig. 8Ce, f) . (Fig. 9B) .
Nuclear IL-33 is produced by sinusoidal endothelial cells in normal liver
Human culture-activated HSC expressed IL-33
Immunocytolocalization of IL-33 in culture-activated HSC (Fig.  9Cb, d ) confirmed the presence of IL-33 in these cells and showed a nuclear subcellular localization. ␣-SMA cytolocalization in activated (myo)fibroblastic HSC served as a positive control (Fig. 9Cc,  d ). These findings thus demonstrated that activated HSC produce the IL-33 pro-form. Fig. 10 , IL-33 mRNA was induced in activated HSC after 6 hrs exposure to the cytokine cocktail (Fig. 10A) (Fig. 10C ). [3, 20, 21] and collagen synthesis [22, 23] . [7] and in mice with cardiac fibrosis [11] . [4, 6, 7, 24] 
IL-33 is induced under pro-inflammatory conditions in culture-activated HSC
The modulation of IL-33 expression in growing HSC was studied in the presence of pro-inflammatory cytokines added alone or in combination. The greatest increase in IL-33 was observed after stimulation with a 'pro-inflammatory cytokine cocktail' containing TNF-␣, IL-1␤, IL-6 and IFN-␥. As shown in
